Safety and Preliminary Efficacy of GQ1001, a Next Generation HER2-targeting ADC, Combined with Pyrotinib in Pretreated Patients with HER2-positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.
JOURNAL OF CLINICAL ONCOLOGY（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined